Alpha-carboxynucleoside phosphonates: direct-acting inhibitors of viral DNA polymerases
نویسندگان
چکیده
منابع مشابه
Viral DNA Polymerases
Because many viruses are readily amenable to molecular, genetic, and biochemical analyses, and because the replication of certain viruses has been the target of antiviral drug development, a wealth of information has accumulated regarding the structure, functions, properties, and regulation of eukaryotic viral DNA polymerases. Viral DNA polymerases have interesting similarities with eukaryotic ...
متن کاملAffinity chromatography of viral DNA polymerases on pyran-sepharose.
Pyran covalently linked to cyanogen bromide-activated Sepharose has been shown to be an effective affinity matrix for several viral DNA polymerases. Differential salt elution of viral compared with cellular polymerases, as well as substrate elution, suggests the affinity nature for the matrix. Unlike some other affinity systems described, pyran-Sepharose is totally resistant to nuclease digesti...
متن کاملComparison of Six Commercially-available Dna Polymerases for Direct Pcr
The use of a "direct PCR" DNA polymerase enables PCR amplification without any prior DNA purification from blood samples due to the enzyme's resistance to inhibitors present in blood components. Such DNA polymerases are now commercially available. We compared the PCR performance of six direct PCR-type DNA polymerases (KOD FX, Mighty Amp, Hemo KlenTaq, Phusion Blood II, KAPA Blood, and BIOTAQ) i...
متن کاملMechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
There has been a remarkable transformation in the treatment of chronic hepatitis C in recent years with the development of direct acting antiviral agents targeting virus encoded proteins important for viral replication including NS3/4A, NS5A and NS5B. These agents have shown high sustained viral response (SVR) rates of more than 90% in phase 2 and phase 3 clinical trials; however, this is sligh...
متن کاملDirect Acting Antivirals for the Treatment of Chronic Viral Hepatitis
The development and evaluation of antiviral agents through carefully designed clinical trials over the last 25 years have heralded a new dawn in the treatment of patients chronically infected with the hepatitis B and C viruses, but not so for the D virus (HBV, HCV, and HDV). The introduction of direct acting antivirals (DDAs) for the treatment of HBV carriers has permitted the long-term use of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Future Medicinal Chemistry
سال: 2019
ISSN: 1756-8919,1756-8927
DOI: 10.4155/fmc-2018-0324